Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Depreciation & Amortization (CF) (2022 - 2025)

Entrada Therapeutics has reported Depreciation & Amortization (CF) over the past 4 years, most recently at $900000.0 for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $900000.0 for Q4 2025, down 10.0% from a year ago — trailing twelve months through Dec 2025 was $4.1 million (up 10.81% YoY), and the annual figure for FY2025 was $4.1 million, up 7.89%.
  • Depreciation & Amortization (CF) for Q4 2025 was $900000.0 at Entrada Therapeutics, down from $1.2 million in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for TRDA hit a ceiling of $1.2 million in Q3 2025 and a floor of $400000.0 in Q1 2022.
  • Median Depreciation & Amortization (CF) over the past 4 years was $850000.0 (2023), compared with a mean of $781437.5.
  • Biggest five-year swings in Depreciation & Amortization (CF): skyrocketed 66.36% in 2024 and later fell 10.0% in 2025.
  • Entrada Therapeutics' Depreciation & Amortization (CF) stood at $526000.0 in 2022, then skyrocketed by 39.92% to $736000.0 in 2023, then soared by 35.87% to $1.0 million in 2024, then fell by 10.0% to $900000.0 in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $900000.0 (Q4 2025), $1.2 million (Q3 2025), and $1.1 million (Q2 2025) per Business Quant data.